Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Identify the ideal low-cost index funds for retirement using transparent criteria and performance benchmarks to guide your choices.
27,037 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
A CFO's $2.1 million sale of OUSTER shares raises questions for investors. This analysis explains what such insider m...
A wave of fresh research notes on Thursday targets a mix of tech and consumer names, including Analog Devices, Chewy,...
An insider move at a biotech stage company can spark questions. This article breaks down the trade, its timing, and w...
Headlines promising simple truths about markets often mislead. This article shows how prices reflect many signals ove...
A single director's sale at MannKind raises questions about the durability of royalty streams. This analysis breaks d...
A Chinese AI named KIMI is making bold end-2026 forecasts for XRP, Ethereum, and Dogecoin, triggering a fresh wave of...
Could Zcash flip Bitcoin? This article breaks down how Zcash’s privacy features, regulatory dynamics, and market tren...
As biotech earnings season unfolds, Precigen (PGEN) 2025 earnings take center stage. This guide breaks down what to m...
Kick off your day with ten concise investing reads tailored for Thursday mornings. From market trends to AI disruptio...
Constellation Energy has moved from a traditional utility to a player tied to data-center power and AI demand. This a...
A quiet, strategic move by a bank’s wealth management arm adds more exposure to its parent company’s stock. Learn wha...